Pleased to share our study in A&R investigating rheum evaluation, immunomodulator use, and predictors of rheumatic immune-related adverse events (irAEs) after immune #checkpoint inhibitor use for cancer, led by @BusselKiki @BrighamResearch @DanaFarber https://t.co/6rnSfd08FB